Presentation (CTI)

OBJECTIVES: In France, the Commission for Economic and Public Health Evaluation (CEESP) provides an economic opinion of the incremental cost-effectiveness ratio (ICER) validity. Since 2016, due to the arrival of immunotherapies, treatment for solid tumor has taken a central position in marketing authorization and reimbursement. The many published opinions in this therapeutic area are likely to create anchoring and learning effects.
This study aims to analyze the CEESP opinions in oncology issued over the past two years (2022-2023) and to compare them with the findings of the previous analysis conducted by Vyoo in 2023 on CEESP assessments of solid tumor dossiers from 2021-2022.
METHODS: Using Vyoo Agency efficiency database, all CEESP opinions in oncology appraised between January 1st, 2023, and December 31st, 2024, were reviewed. An opinion is valid if there are no mention of major uncertainty or objection.
RESULTS: Over the two years, 10 CEESP opinions concerned drugs for solid tumor (-62% versus 2021-2022) on 5 different tumoral sites. They included neither major objection nor global uncertainty for 90% (+21% versus 2021-2022) of the dossiers. For those 10 dossiers, the average ICER is €147,144.75 per QALY (+17.73% versus 2022-2023) and ranges from €23,355/QALY to €321,002 per QALY (-29.47% and +7% versus 2021-2022 respectively) and one opinion concluded that the drug is dominant.
Of the 10 economic opinions, 5 concerned Monoclonal Antibodies, with a validated ICER. The dominant RDCR is in the breast cancer area.
CONCLUSIONS: Over the two years considered for the analysis (2022-2023), CEESP has delivered 39 opinions, including 20 with a validated ICER (51%). Opinions on solid tumor comprised 25% of all opinions appraised during this period and they are characterized by a higher proportion of validated opinions (90%). To conclude, it seems that HE assessment in oncology is now well framed and consequently confers advantages to meet the CEESP expectations.